Insurance Denied Proton Therapy? How to Build Your Appeal

Proton beam therapy is an advanced form of radiation oncology that delivers radiation with precision unavailable with conventional photon therapy. For specific cancers — particularly in pediatric patients and cases where minimizing radiation to surrounding tissue is critical — it represents a meaningful clinical advantage. Despite this, insurers routinely deny proton therapy as "investigational" or "not superior to standard radiation," ignoring the established evidence and specialty society endorsement.

Why Insurers Deny Proton Therapy

• "Not clinically superior to photon radiation": Insurers cite randomized controlled trial limitations — few completed RCTs exist because randomization to potentially inferior treatment is ethically and practically difficult in radiation oncology
• "Investigational or experimental": Applied selectively to proton therapy despite decades of clinical use and availability at major cancer centers
• "Less costly alternative available": Insurer argues that IMRT or other photon approaches are adequate without performing a patient-specific analysis
• "Not medically necessary for this indication": Insurer restricts coverage to specific tumor types even when clinical evidence supports broader use
• Site-of-service or network issues: Proton centers are less common; patients may face network-based denials requiring travel to in-network facilities

How to Appeal a Proton Therapy Denial

Step 1: Obtain the Denial Letter and Insurer's Clinical Criteria

Request the specific clinical policy bulletin the insurer applied. Compare it against ASTRO model coverage policy to identify discrepancies. Under ERISA (29 U.S.C. § 1133), the insurer must provide these criteria documents.

Step 2: Cite ASTRO Model Coverage Policy

The American Society for Radiation Oncology (ASTRO) publishes model coverage policies and clinical practice statements that represent the standard of care in radiation oncology. ASTRO recognizes proton therapy as clinically appropriate (not investigational) for: uveal melanoma, chordoma and chondrosarcoma of the skull base and spine, pediatric CNS tumors (medulloblastoma, ependymoma, glioma), pediatric solid tumors (Ewing sarcoma, rhabdomyosarcoma), prostate cancer, locally advanced NSCLC, hepatocellular carcinoma, head and neck cancers, and breast cancer with internal mammary node involvement. Cite the specific indication from ASTRO's model coverage policy document.

Step 3: Request a Dosimetric Comparison Plan

Ask your radiation oncologist to provide a dosimetric comparison plan — a dose-volume histogram (DVH) showing the radiation dose difference between proton and photon approaches for your specific anatomy. This is often the most compelling evidence in a proton therapy appeal. Physical dosimetric superiority (the Bragg peak effect) can be demonstrated even when clinical outcome RCTs are limited.

Step 4: Make the Pediatric Case Explicitly

For pediatric cancer patients, the argument for proton therapy is particularly strong. Children's developing brains and bodies are significantly more sensitive to radiation damage. The Children's Oncology Group (COG) and pediatric radiation oncology community strongly favor proton therapy for CNS tumors and other childhood cancers where dose reduction to normal tissue is critical. Published economic analyses document long-term cost savings from avoiding secondary cancers, neurocognitive interventions, and growth hormone therapy in childhood cancer survivors. For a child with medulloblastoma or craniopharyngioma, denial of proton therapy is clinically, ethically, and potentially legally problematic.

Step 5: Counter the RCT Limitation Argument

Cite that RCT design limitations are inherent to radiation oncology — patients, physicians, and institutions are often unwilling to randomize to potentially inferior treatment. The absence of completed RCTs is not evidence of inefficacy. Published comparative outcomes data, institutional series, registry studies, and prospective cohort studies support proton therapy outcomes.

Step 6: Request Peer-to-Peer Review and External IMR

Request a peer-to-peer review between your radiation oncologist and the insurer's medical director. If the internal appeal fails, request external IMR — proton therapy appeals reviewed by radiation oncologists overturn at high rates when supported by ASTRO guidelines and dosimetric evidence.

What to Include in Your Appeal

• ASTRO model coverage policy citation for your specific cancer type and indication
• Dosimetric comparison plan (DVH) from your radiation oncologist showing dose reduction to critical structures with proton vs. photon
• Children's Oncology Group (COG) guidelines for pediatric cancer cases
• Radiation oncologist's letter of medical necessity citing site-specific clinical rationale
• Challenge to "investigational" designation using your policy's definition language and ASTRO's professional endorsement

Fight Back With ClaimBack

Proton therapy denials resting on outdated "investigational" criteria or the absence of RCTs are overturned at high rates when ASTRO guidelines and dosimetric evidence are properly presented. ClaimBack generates a professional appeal letter in 3 minutes. Start your free claim analysis → Free analysis · No credit card required · Takes 3 minutes

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs External Insurance Appeal